Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605899 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
A Phase 3 study of High-risk Large B-cell Lymphoma (LBCL), sponsored by Kite, A Gilead Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT05605899 is a Phase 3 study of High-risk Large B-cell Lymphoma (LBCL) that is actively recruiting participants, run by Kite, A Gilead Company. The registered enrollment target is 300 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05605899, a Phase 3 study of High-risk Large B-cell Lymphoma (LBCL), is actively recruiting participants, sponsored by Kite, A Gilead Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG Etoposide
- BIOLOGICAL Axicabtagene Ciloleucel
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California Los Angeles (UCLA) - Los Angeles
- Stanford Cancer Institute - Palo Alto
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic - Phoenix
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Medical Center - Chicago
Alabama
- University of Alabama Hospital - Birmingham
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Georgia Cancer Center at Augusta University - Augusta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2031-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05605899
The ClinicalTrials.gov registry entry for NCT05605899 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-risk Large B-cell Lymphoma (LBCL) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05605899 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT05605899 about?
NCT05605899 is a clinical study titled "Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma". The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
What is the current status of trial NCT05605899?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2023-02-10. Estimated completion is 2031-03.
What conditions does trial NCT05605899 study?
This clinical trial studies the following conditions: High-risk Large B-cell Lymphoma (LBCL).
What interventions are being tested in trial NCT05605899?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), Etoposide (DRUG), Axicabtagene Ciloleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT05605899?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05605899 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.